Production (Stage)
Xeris Biopharma Holdings, Inc.
XERS
$4.83
-$0.05-1.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -9.22M | -5.11M | -15.74M | -15.01M | -18.98M |
| Total Depreciation and Amortization | 3.14M | 3.13M | 3.12M | 3.15M | 3.21M |
| Total Amortization of Deferred Charges | 844.00K | 824.00K | 803.00K | 807.00K | 573.00K |
| Total Other Non-Cash Items | 4.44M | 3.61M | 2.83M | 4.08M | 523.00K |
| Change in Net Operating Assets | -9.24M | -474.00K | 674.00K | -3.39M | -5.63M |
| Cash from Operations | -10.03M | 1.98M | -8.31M | -10.35M | -20.30M |
| Capital Expenditure | -13.00K | -220.00K | -87.00K | -397.00K | -164.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 10.24M | 10.00M | 5.00M | -19.49M |
| Cash from Investing | -13.00K | 10.02M | 9.91M | 4.60M | -19.65M |
| Total Debt Issued | -- | 0.00 | 0.00 | 0.00 | 50.00M |
| Total Debt Repaid | -- | -- | 11.83M | -11.83M | -- |
| Issuance of Common Stock | 4.86M | 564.00K | 0.00 | 710.00K | 459.00K |
| Repurchase of Common Stock | -8.00M | -166.00K | -83.00K | -51.00K | -3.43M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -11.83M | 11.83M | -11.83M |
| Cash from Financing | -3.14M | 398.00K | -83.00K | 659.00K | 35.19M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.18M | 12.39M | 1.53M | -5.09M | -4.76M |